‘Earning’ Power
The job of pharma-driven messaging and reputation management may never be more important than it is today.
Although perhaps a bit dizzy trying to keep up, like most industries, the pharmaceutical and healthcare sectors have no doubt been glued to the flurry of major changes carried out or announced by the US government in recent months. Whether it’s the Trump administration issuing sweeping global tariffs on imports or the significant overhauls already taking shape at several federal agencies, including those under the HHS.
No matter which side of the debate you may fall on, the reverberations across the industry, of course, will be many. In the case of agency reform, and changes favored by new HHS Secretary Robert F. Kennedy Jr., the fallout could usher in drastic policy shifts impacting pharmaceutical marketing, including a potential ban on direct-to-consumer advertising. Check out our Q&A in this month’s issue on how brand teams are strategizing for such a scenario—and how that type of change, broadly, could actually serve as a catalyst.
Given the climate noted—the volatility, uncertainty, but also the opportunity—the job of pharma-driven messaging and reputation management may never be more important than it is today. Which brings me to the crux of this writing. Not to be overlooked in a full coverage slate this month is the debut of Pharm Exec’s Earned Media series, where our editorial content leaders themselves, across MJH Life Sciences’ vast network of brands, share their unique learnings and insights on ways drugmakers can flip the script—and better land and leverage those coveted earned media opportunities.
“The best way to cut through the noise is for companies to position themselves as trusted, go-to sources for their respective specialties,” offers Allie Karas, VP of content in the specialty healthcare group.
Read more advice in the full Q&A with Allie. We hope you find the insights helpful.
Thanks for reading.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
